Myriad Genetics (MYGN) Accumulated Expenses (2010 - 2026)

Myriad Genetics has disclosed Accumulated Expenses across 17 years of filings, most recently posting $90.5 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 19.27% year-over-year to $90.5 million; the TTM figure through Mar 2026 stood at $90.5 million (down 19.27% YoY), while the FY2025 annual figure was $96.9 million, down 18.57% from the prior year.
• Accumulated Expenses eased to $90.5 million in Q1 2026, from $96.9 million in the prior quarter.
• Over the last five years, Accumulated Expenses for MYGN reached as high as $164.3 million in Q2 2023 and fell as low as $84.4 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $100.6 million (2025), against an average of $109.0 million.
• Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 47.73% — and 2023, when it surged 94.67%.
• A 5-year view of Accumulated Expenses shows it stood at $94.3 million in 2022, then gained by 20.78% to $113.9 million in 2023, then gained by 4.48% to $119.0 million in 2024, then retreated by 18.57% to $96.9 million in 2025, then declined by 6.6% to $90.5 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $90.5 million, $96.9 million, and $108.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.